| Literature DB >> 33966146 |
Klaudia Rakusiewicz1, Krystyna Kanigowska2, Wojciech Hautz2, Lidia Ziółkowska3.
Abstract
PURPOSE: To evaluate choroidal thickness (CTh) in children with chronic heart failure (CHF) secondary to dilated cardiomyopathy (DCM) using spectral domain optical coherence tomography (SD-OCT) and to compare their values to those of healthy children.Entities:
Keywords: Choroidal thickness; Chronic heart failure; Dilated cardiomyopathy; Optical coherence tomography
Mesh:
Year: 2021 PMID: 33966146 PMCID: PMC8172512 DOI: 10.1007/s10792-021-01774-5
Source DB: PubMed Journal: Int Ophthalmol ISSN: 0165-5701 Impact factor: 2.031
Fig. 1Manual measurement of choroidal thickness by the investigator using spectral domain optical coherence tomography
Demographic and clinical features in dilated cardiomyopathy patients and control subjects
| Variable | Study group | M | SD | 95% CI | Range | |
|---|---|---|---|---|---|---|
| NT-proBNP (pg/ml) | DCM group | 568.10 | 1045.27 | 177.79–958.41 | 15–3723 | – |
| LVEF (%) | DCM group | 49.03 | 6.63 | 46.56–51.51 | 30–55 | – |
| Age (years) | DCM group | 9.9 | 3.57 | 8.57–11.23 | 5–17 | 0.68 |
| Control | 10.16 | 3.42 | 9.03–11.28 | 4–16 | ||
| Biometry (mm) | DCM group | 22.17 | 0.88 | 21.85–22.5 | 20.615–24.08 | 0.09 |
| Control | 22.49 | 0.63 | 22.29–22.7 | 21.1–23.795 | ||
| Spherical refractive error | DCM group | 0.75 | 1.14 | 0.32–1.17 | − 2.00–3.00 | 0.45 |
| Control | 0.56 | 1.18 | 0.17–0.94 | − 2.25–2.75 | ||
| Cylindrical refractive error | DCM group | 0.17 | 0.29 | 0.06–0.28 | 0.00–1.25 | 0.1 |
| Control | 0.26 | 0.35 | 0.15–0.38 | 0.00–1.00 |
M mean, SD standard deviation, CI confidence interval, LVEF left ventricular ejection fraction, NT-proBNP natriuretic peptide type B, DCM group group with dilated cardiomyopathy
Choroidal thickness at individual locations in dilated cardiomyopathy patients and control subjects
| Variable | Study Group | M | SD | 95% CI | Range | |
|---|---|---|---|---|---|---|
| SFCTh | DCM group | 304.03 | 63.03 | 280.5–327.57 | 145.5–405.5 | < 0.05 |
| Control group | 369.72 | 55.79 | 351.39–388.06 | 263.5–503 | ||
| Nasal CTh | DCM group | 245.87 | 68.28 | 220.37–271.36 | 129–402.5 | < 0.05 |
| Control group | 284 | 63.2 | 263.23–304.77 | 194–453 | ||
| Temporal CTh | DCM group | 291.5 | 57.12 | 270.17–312.83 | 169.5–405 | < 0.05 |
| Control group | 355.95 | 61.77 | 335.64–376.25 | 237–500 | ||
| Superior CTh | DCM group | 303.98 | 58.38 | 282.18–325.78 | 203.5–401.5 | < 0.05 |
| Control group | 357.58 | 50.87 | 340.86–374.3 | 257–460.5 | ||
| Inferior CTh | DCM group | 290.92 | 52.59 | 271.28–310.55 | 180–404 | < 0.05 |
| Control group | 344.96 | 48.48 | 329.03–360.89 | 255–499.5 |
M mean, SD standard deviation, CI confidence interval, SFCTh subfoveal choroidal thickness, CTh choroidal thickness
Fig. 2Manual measurement of choroidal thickness by the investigator using the spectral domain of coherent optical tomography (a) in a patient with dilated cardiomyopathy (b) in a control group
Fig. 3Central tendency and dispersion for choroidal thickness (μm) at selected anatomical locations in the study sample by DCM status and sex. The box is drawn from the first quartile to the third obtained data values, in the middle a thick horizontal line indicates a median. The whiskers are used to determine the minimum and maximum value: the lowest data point excluding any outliers is the minimum value, and the highest data point excluding any outliers is the maximum value
Fig. 4Graph of correlation between subfoveal choroidal thickness (SFCTh) and N-terminal (NT)-pro hormone BNP (NT-proBNP) and left ventricular ejection fraction (LVEF)